Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

被引：18
|
作者：
Moy, Beverly [1 ,4 ]
Rumble, R. Bryan [2 ]
Carey, Lisa A. [3 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA USA
[2] Amer Soc Clin Oncol, Alexandria, VA USA
[3] UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[4] Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 06期
关键词：
D O I：
10.1200/JCO.22.02807
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
引用
收藏
页码：1318 / +
页数：4
相关论文
共 50 条
  • [1] Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update
    Moy, Beverly
    Rumble, Bryan
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (26) : 3088 - +
  • [2] Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A
    Moy, Beverly
    Wolff, Antonio C.
    Rumble, R. Bryan
    Allison, Kimberly H.
    Carey, Lisa A.
    JCO ONCOLOGY PRACTICE, 2023, 19 (08) : 547 - +
  • [3] Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update
    Moy, Beverly
    Rumble, R. Bryan
    Come, Steven E.
    Davidson, Nancy E.
    Di Leo, Angelo
    Gralow, Julie R.
    Hortobagyi, Gabriel N.
    Yee, Douglas
    Smith, Ian E.
    Chavez-MacGregor, Mariana
    Nanda, Rita
    McArthur, Heather L.
    Spring, Laura
    Reeder-Hayes, Katherine E.
    Ruddy, Kathryn J.
    Unger, Paul S.
    Vinayak, Shaveta
    Irvin, William J., Jr.
    Armaghani, Avan
    Danso, Michael A.
    Dickson, Natalie
    Turner, Sophie S.
    Perkins, Cheryl L.
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (35) : 3938 - +
  • [4] Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update
    Giordano, Sharon H.
    Freedman, Rachel A.
    Somerfield, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (03) : 307 - +
  • [5] Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
    Nina Tamirisa
    Kelly K. Hunt
    Annals of Surgical Oncology, 2022, 29 : 1489 - 1492
  • [6] Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
    Tamirisa, Nina
    Hunt, Kelly K.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (03) : 1489 - 1492
  • [7] Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
    Korde, Larissa A.
    Somerfield, Mark R.
    Carey, Lisa A.
    Crews, Jennie R.
    Denduluri, Neelima
    Hwang, E. Shelley
    Khan, Seema A.
    Loibl, Sibylle
    Morris, Elizabeth A.
    Perez, Alejandra
    Regan, Meredith M.
    Spears, Patricia A.
    Sudheendra, Preeti K.
    Symmans, W. Fraser
    Yung, Rachel L.
    Harvey, Brittany E.
    Hershman, Dawn L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (13) : 1485 - +
  • [8] Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update
    Burstein, Harold J.
    Somerfield, Mark R.
    Barton, Debra L.
    Dorris, Ali
    Fallowfield, Lesley J.
    Jain, Dharamvir
    Johnston, Stephen R. D.
    Korde, Larissa A.
    Litton, Jennifer K.
    Macrae, Erin R.
    Peterson, Lindsay L.
    Vikas, Praveen
    Yung, Rachel L.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (35) : 3959 - +
  • [9] Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update
    Burstein, Harold J.
    DeMichele, Angela
    Fallowfield, Lesley
    Somerfield, Mark R.
    Henry, N. Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (12) : 1450 - 1453
  • [10] Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update
    Denduluri, Neelima
    Somerfield, Mark R.
    Chavez-MacGregor, Mariana
    Comander, Amy H.
    Dayao, Zoneddy
    Eisen, Andrea
    Freedman, Rachel A.
    Gopalakrishnan, Ragisha
    Graff, Stephanie L.
    Hassett, Michael J.
    King, Tari A.
    Lyman, Gary H.
    Maupin, Gillian Rice
    Nunes, Raquel
    Perkins, Cheryl L.
    Telli, Melinda L.
    Trudeau, Maureen E.
    Wolff, Antonio C.
    Giordano, Sharon H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06) : 685 - +
12345